Background: Viruses resistant to zanamivir have been generated in vitro, but no resistant virus has yet been isolated from a zanamivir-treated immunocompetent patient. In contrast most resistant viruses isolated from oseltamivir-treated patients correspond to those selected in vitro. However, despite mutations being in conserved residues in the neuraminidase (NA) they do not confer resistance in all NA subtypes.
Introduction
The influenza neuraminidase (NA) plays a critical role in the spread of virus during replication. The NA facilitates elution of progeny virions from infected cells and prevents virus aggregation by removal of terminal sialic acid residues, both from cellular receptors and from virions themselves. Determination of the structure of NA complexed with sialic acid 1 led to the development of zanamivir 2 and subsequently oseltamivir, 3 both of which are licensed for the treatment and in many countries for the prophylaxis of influenza infections. A third inhibitor, peramivir, was also developed, 4 However, as it has features of both zanamivir and oseltamivir it is also useful for understanding molecular interactions leading to resistance in the NA. Due to the high degree of conservation in the active site, each of the NA inhibitors is effective against all strains of influenza. All inhibitors are based on the structure of 2, 3-dehydro-2-deoxy-N-acetyl neuraminic acid (DANA), a transition state analogue of sialic acid generated during catalysis ( Figure 1 ). The initial inhibitor synthesized had a single substitution of the O-4 hydroxyl group of DANA with an amino group (4-amino Neu5Ac2en). This resulted in a 100-fold increase in inhibitory efficacy over DANA. The single substitution of the O-4 hydroxyl group with a guanidinium group to generate zanamivir conferred a 10 000-fold increase in efficacy. Oseltamivir has several differences to DANA, being based on a cyclohexene ring, but in addition having substitutions of an amino group at the 4 0 position and a bulky hydrophobic pentyl ether replacing the glycerol side chain at the 6 0 position. Peramivir is based on a cyclopentane ring, but has modifications of both a guanidinium group corresponding to the 4 0 position of DANA, as well as a hydrophobic group at the DANA equivalent of the 6 0 position (Figure 1 ). In order to bind oseltamivir and peramivir the active site is modified by the creation of a hydrophobic pocket where the glycerol binds, by generating an internal salt link between E276 and R224. 6, 7 This permits engagement of the hydrophobic group at the 6 0 position. Resistance to zanamivir has been generated in vitro in influenza A N2 (E119G, D, A, R292K) 8, 9 and N9 (E119G, R292K) 10, 11 and in influenza B (E119G, D). [12] [13] [14] No resistant
virus has yet been isolated from an immunocompetent patient treated with zanamivir. One influenza B virus with decreased sensitivity to zanamivir and oseltamivir was isolated from an immunocompromised patient treated with zanamivir, but it had a novel mutation (R152K) not previously seen in vitro. 15 However, many of the strains used as models for zanamivir resistance studies have been laboratory-generated reassortants of avian viruses, A/NWS/G70C (H1N9) and A/Turkey/Minnesota (H4N2). In contrast, several resistant viruses have been isolated from oseltamivir-treated patients, with some of the mutations corresponding to those generated in vitro (R292K, E119V in N2 viruses, and H274Y in N1). [16] [17] [18] [19] Due to the differences in the chemical structures of zanamivir and oseltamivir there are mutations which may only confer resistance to one of the inhibitors. Furthermore despite residues in and around the active site being highly conserved, some of the mutations only confer resistance in one NA subtype, i.e. they only confer oseltamivir resistance in N1 (H274Y) or N2 (R292K, E119V). Those mutations which result in decreased binding of the inhibitors are in the regions which interact with the sites on the inhibitors that differ from the DANA intermediate, i.e. the 4-guanidino on zanamivir and peramivir and the 4-amino and 6-amino substitutions on oseltamivir and peramivir. The carboxylate group of E119 interacts with the guanidinium group of zanamivir and peramivir, hence an E119G mutation confers resistance to both these inhibitors, but not to oseltamivir in N2, N9 and B NAs. Mutations of E119 to A or D affect binding of both zanamivir and oseltamivir, but with a greater effect on zanamivir binding. 13, 20 As mutations at E119 confer resistance in so many different NAs it is surprising that E119G, A and D have not yet been seen after zanamivir treatment in vivo. In contrast, N2 viruses with an E119V mutation have been isolated from patients after oseltamivir treatment. 18 Although E119 is a key amino acid involved in binding the guanidinium group of zanamivir, unexpectedly, this E119V mutation does not confer resistance to zanamivir. 21 Reverse genetics has recently been used to generate influenza B and H1N1 viruses with NA mutations previously associated with resistance to NA inhibitors of B, N1 and N2 subtypes. 20, 22 Viable viruses with mutations known to confer either zanamivir or oseltamivir resistance in N2 NAs, R292K, E119G, V, A or D could not be generated in the N1 background. In contrast viable viruses harbouring E119G, V, A and D, R292K and R152K were all isolated in influenza B viruses. 20 We have used reverse genetics to investigate the effects that mutations which confer zanamivir resistance in vitro have on the NA of a recent clinical H3N2 isolate, A/Sydney/5/97, as well as on the A/Tokyo/67 N2 NA, the structure of which was used for the original design of zanamivir. We have also used the baculovirus system to investigate the effects of some of these mutations on the A/Tokyo/ 67 N2 as well as the G70C N9 NAs to try to gain a greater understanding of subtype-specific drug resistance. Figure 1 . Chemical structures of the neuraminidase inhibitor drugs used in the study.
Materials and methods
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serum-free DMEM at 37 C in the presence of 2.5 mg of trypsin/mL. Viruses for NA-STAR-based chemiluminescent (CL) NA activity assays were grown in serum-free DMEM lacking phenol red (Life Technologies). The N9 NA gene was cloned from the A/NWS/G70C reassortant, which contains the NA of the A/tern/Australia/G70C/75 (G70C) virus and all other genes from the NWS parent.
293T cells (human embryonic kidney cells) and Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies) supplemented with 10% fetal calf serum, 1% glutamine (200 mM), 2% non-essential amino acids and 1% penicillin-streptomycin (5000 IU/mL; 5000 mL) at 37 C and 5% CO 2 . Sf21 insect cells were maintained in Sf900II serum-free insect culture medium (Invitrogen, USA).
Plasmid construction
A cassette vector, pPRG, was generated, which allows the cloning of the influenza virus gene segments, so they were flanked by a human polymerase I promoter at the 5 0 terminus and the hepatitis delta virus ribozyme at the 3 0 terminus. 23 The distal cleavage sites of restriction enzymes SapI or BsmBI enable the exact insertion of viral genes. The polymerase I promoter was cloned from a human genomic library by PCR using primers based upon published sequences. 24 The ribozyme sequence used was the antigenomic sense ribozyme of hepatitis delta virus (kindly provided by Dr A. Ball). The influenza virus genes were cloned by reverse transcription-PCR or plasmid PCR, using appropriate primers complementary to the end of the gene including a SapI or BsmBI restriction site for the insertion into pPRGSapI or pPRG-BsmBI vector, respectively (primer sequences are available on request). The NA segment of the A/NWS/Tokyo/67 (H1N2) was subcloned from the baculovirus pBakPak9 vector. The haemagglutinin (HA) of A/Victoria/3/75 (H3N2) virus and NA segments of influenza A/Sydney/5/97 (H3N2) were amplified from viral RNA and the remaining gene segments of A/Victoria/3/75 (H3N2) virus were amplified from plasmids. 25, 26 A set of pCMV expression plasmids was constructed by inserting the open reading frames of the polymerase genes and NP into pcDNA3. The Quick Change site-directed mutagenesis kit (Stratagene, USA) was used for generation of E119A/D/G/V, R152K, H274Y and R292K mutant NAs. A FLAG tag was incorporated into the stalk region, between amino acids 45 and 54 by PCR.
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Transfection and rescue of recombinant viruses Influenza A virus rescue was performed as described previously. Briefly, 0.5 mg of pPRPB1, pPRPB2, pPRPA, pPRHA, pPRNP, pPRNA, pPRM, pPRNS, pCMV-PB1, pCMV-PB2 and 0.05 mg of pCMV-PA and 1 mg of pCMV-NP were transfected into subconfluent 293T cells on a 12-well plate using 20 mL of FuGENE 6 transfection reagent (Roche Molecular Biochemicals). After incubation overnight at 37 C, transfected 293T cells were trypsinized and co-cultured with MDCK in DMEM/10% fetal calf serum. After 8 h of incubation at 37 C the medium was replaced by serumfree DMEM containing 2.5 mg of trypsin/mL. Some NA mutations are known to compromise virus infectivity, but the viruses can grow to normal titres with an external source of NA. Therefore recombinant viruses were rescued in both the presence and absence of Clostridium perfringens NA (10 mU/mL, Sigma). Cells were incubated at 37 C until cytopathic effect was observed 68-72 h post-transfection. The NA and HA genes of all recombinant viruses were sequenced by RT-PCR from rescued virus and after further passage in MDCK cells.
Baculovirus expression
The gene coding for the A/Tokyo/67 NA had been previously cloned into the pBakPak9 vector following the manufacturer's protocols (Invitrogen, USA), hence this was used as the template for mutagenesis. The gene coding for the full-length A/tern/Australia/ G70C/75 N9 NA was cloned into the pFastBac1 vector following the manufacturer's protocol (Invitrogen, USA). Sf21 cells were transfected with the bacmid DNA using FuGENE (Roche Diagnostics, USA), and recombinant virus was amplified in Sf21 cells. Mutations in the NA genes were generated using the Quick Change (Stratagene, USA) site-directed mutagenesis kit.
NA enzyme inhibition assays
The NA inhibitors 4-aminoNeu5Ac2en, zanamivir (GG167), oseltamivir (GS4071) and peramivir (RWJ270201) were synthesized at GlaxoSmithKline, Stevenage, UK. NA activity of each rescued recombinant influenza virus was titrated in the NA-STAR based CL assay. 28 Briefly serial 2-fold dilutions of virus supernatants were incubated with substrate at 37 C for 15 min. Sapphire II enhancer was added to each well and plates were read immediately in a Victor 1420 multilabel counter (Wallac) using a protocol with a luminescence label, no excitation, no filter and a counting time of 0.1 s per well. A dilution of virus which gave approximately a 40:1 signal to noise ratio was used for the inhibition assays. For inhibition assays, a 3 mM stock solution of each drug in water was serially diluted 3-fold from 0.55 mM to 0.028 nM in water. Virus samples were preincubated with 10 mL drug for 30 min at room temperature followed by the addition of substrate and incubation for 15 min at 37 C. Plates were read immediately after the addition of enhancer.
For recombinant NA expressed in insect cells, NA activity was measured using the 4-methyl-umbelliferyl-N-acetyl neuraminic acid (MUNANA) fluorescence-based assay as described previously.
11 As the NA is expressed on the cell surface, cells were lysed in 1% TX100 to make soluble extracts. Assays were incubated for 1 h at 37 C and stopped by the addition of 0.2 M Na 2 CO 3 . Plates were read in a Perkin Elmer fluorimeter, with an excitation wavelength of 360 nm and an emission wavelength of 465 nm. A dilution of each extract which gave NA activity in the linear portion of the curve was used for the inhibition assays. Extracts were pre-incubated for 30 min with serial 10-fold dilutions of each of the inhibitors, ranging from 10 mM to 0.1 nM for zanamivir and oseltamivir, 1 mM to 0.01 nM for peramivir and 5 mM to 0.01 mM for 4-aminoNeu5Ac2en, followed by the addition of substrate. Assays were stopped after 1 h incubation and read in the fluorimeter.
Relative NA activity
Since not all viruses stably expressing the mutant NAs could be rescued using reverse genetics, each of the mutant NAs was expressed in 293T cells and whole cells were used to assay protein expression and NA activity. Transfection of 293T cells in four wells of a 6-well plate was carried out with four helper plasmids (pCMV-PB1, PB2, PA and NP) and the required pPRPNA plasmid as described for the generation of recombinant virus, with the exception that cells were not grown in the presence of trypsin. At 1 day post-transfection 0.5 mL of DMEM containing 10% FCS was added.
At 48 h post-transfection 1 mL of cell dissociation solution (Sigma C5914) was added to each well and incubated at 37 C for 5 min. Cells transfected with the same plasmid were pooled and counted.
NA activity of dilutions of transfected cells was determined using the CL assay and the mean activity was expressed as a percentage of the wild-type activity.
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Levels of protein were determined by fluorescence-activated cell sorting (FACS) analysis of transfected cells, using a polyclonal sheep anti-NA antibody or a monoclonal anti-FLAG antibody, or dual staining with both antibodies. For FACS analysis 10 6 cells were washed three times in wash buffer (PBS containing 2.5% FCS and 0.1% sodium azide), resuspended in 10 mL of primary antibody (polyclonal antiserum raised against H7N2 influenza virus diluted 1:10 000 in wash buffer or anti-FLAG antibody diluted 1:88), vortexed and incubated at room temperature for 10 min. The cells were then washed again, resuspended in 10 mL of secondary antibody [Alexa conjugated anti-sheep IgG diluted 1:40 (Molecular Probes A11015) or phycoerythrin (PE) conjugated anti-mouse IgG diluted 1:20 (Sigma P-9670)] and incubated at room temperature for 10 min. The excess of secondary antibody was removed by washes and cells were analysed in a flow cytometer EPICSÒ XL TM 9 (Beckman Coulter). Mock transfected and untransfected control cells were incubated with sheep IgG (11.4 mg/mL Sigma I-8265) diluted 1:40 or mouse IgG1 (1 mg/mL Sigma M-5284) diluted 1:20.
The relative activity of the mutant NAs compared with the wildtype NAs was determined by comparing the NA activity in serial dilutions of transfected cells with the amount of NA protein on the surface. For activity titrations the first dilution contained 10 5 cells and the mean activity was expressed as a percentage of the wild-type activity.
The relative activities of the recombinant NAs expressed in the baculovirus system were determined by comparing the amounts of enzyme activity in serial dilutions of detergent lysates of infected Sf21 cells with the amount of NA-specific protein in the same dilutions as described previously. 29 NA proteins were captured on to an ELISA plate coated with an NA conformational specific monoclonal antibody, either NC10 for the G70C N9 NAs 30 or 17B (generated at CSIRO) for the A/Tokyo/67 N2 NAs. Each captures only correctly folded NA. The amount of NA bound was detected by reaction with a polyclonal rabbit anti-NA (made at CSIRO by immunizing rabbits with purified NA) 31 and reaction with sheep antirabbit-HRPO conjugate (Silenus Laboratories, Australia).
Kinetics of replication
MDCK cells were infected with the wild-type or stable mutant viruses, E119V, E119D and R292K at an moi of 0.001 to determine the effects of the mutations on virus growth. Samples were harvested at 24, 36, 48 and 60 h post-infection, and yields were assayed by plaque assay in MDCK cells as described previously. 12 Thermal stability of the NA Detergent lysates of insect cells expressing the Tokyo N2 R152K NA were assayed for NA activity in the MUNANA-based assay. Samples of extract which had activity in the linear portion of the graph were then pre-incubated for 1 h at 4, 37, 45, 50, 55 and 60 C. MUNANA was then added and samples were incubated for 1 h. The reaction was stopped with 0.2 M Na 2 CO 3 and the plates were read in the fluorimeter. Percentage of residual activity was calculated for samples incubated at 37-60 C compared with the activity of the sample held at 4 C.
Results
Generation of recombinant influenza viruses
The recombinant A/Victoria/3/75 viruses expressing the wild-type A/Sydney/5/97 (rVic/Sydney NA) or A/Tokyo/67 (rVic/Tokyo NA) NAs were successfully obtained. As a positive control for a mutation known to confer resistance in an N2 NA, the R292K mutation was generated in the A/Sydney/5/97 NA. Recombinant virus was successfully rescued without the need for exogenous NA, even though this mutation has been previously shown to result in significantly reduced NA activity and virus growth.
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Sequencing confirmed that the K292 mutation was present and was stable after passage of the recombinant virus in MDCK cells (see Table 1 ). However, viruses expressing the E119G NA, which confers zanamivir-specific resistance, could only be rescued after transfection in the presence of exogenous NA for both the rVic/ Sydney and rVic/Tokyo viruses, suggesting that the E119G NAs had compromised virus viability (Tables 1 and 2 ). After passage of the E119G rVic/Sydney virus in the absence of exogenous NA, the only virus isolated was that which had mutated to express the wild-type E119 NA. In the case of the rVic/Tokyo E119G mutant the codon was changed at two positions (GAA-GGC) so that reversion to E119 would require two changes. After passage of the E119G rVic/Tokyo virus in the absence of exogenous NA the only progeny isolated were those which had mutated to express an NA with an E119V. Similarly the rVic/Sydney virus with an E119A NA could not be rescued or passaged in the absence of exogenous NA, selecting for either viruses with the wild-type NA or with an E119V NA. 
AA, amino acid; neg, no virus rescued. Underlining indicates that the progeny differ from the original mutant. a-d Independent passaging events.
Progeny from both viruses with the E119V mutation were rescued after transfection without the need for exogenous NA, and progeny maintained the mutation on further passaging. This is consistent with isolation of viable viruses with the E119V mutation from clinical isolates after treatment with oseltamivir. 18 An influenza B virus with an R152K mutation was isolated from an immunocompromised patient after prolonged treatment with zanamivir. 15 To investigate whether this could also confer zanamivir resistance in the N2 background this mutation was generated in both the plasmids coding for the A/Sydney/5/97 and A/Tokyo/67 NAs. However, as with some of the E119 mutations, R152K mutant viruses could not be rescued after transfection in the absence of exogenous NA, again suggesting that the mutant viruses were too compromised to survive. The rVic/Sydney R152K NA virus isolated with the exogenous NA was passaged in two independent experiments. Wild-type R152 virus was isolated in one experiment and mutant K152 progeny were isolated in the second. For the recombinant rVic/Tokyo R152K mutant only reverted, wild-type progeny were isolated.
Viruses with the H274Y mutation were rescued without the use of exogenous NA and the genotype was stably inherited in both recombinant viruses. This is a mutation which confers oseltamivir-specific resistance in N1 but not N2 viruses. 16, 32 This would be consistent with it having no significant detrimental effect on either of the N2 NAs tested here.
Silent mutations present in all the NA mutant plasmids identified the rescued virus as genuine revertants. The HA genes of all rescued mutants were sequenced and no changes were observed.
Expression of H274Y and R152K proteins in insect cells
Our results suggested that the R152K mutant protein compromised the viability of the recombinant viruses. To ensure that the protein itself could be correctly folded and produced as a functional protein in the N2 NA, we also used the baculovirus expression system to produce both the R152K and the H274Y proteins in insect cells. We know that the N2 specific R292K mutation confers resistance in the G70C N9 NA, hence it has been a useful model for understanding the mechanism of resistance of N2 mutations. 7, 10, 18, 33 We therefore used both the A/Tokyo/67 N2 and G70C N9 NAs to further investigate subtype-specific resistance in the insect cell system. All the wild-type and mutant proteins were successfully expressed as correctly folded proteins, based on reactivity with conformational specific monoclonal antibodies (Materials and methods). All NAs also had some enzyme activity. Hence the R152K protein can be correctly folded suggesting that the poor viability of the recombinant influenza viruses must be due to their poorly functional enzyme. The availability of these recombinant proteins allowed us to further characterize subtype-specific drug resistance.
Drug sensitivity Recombinant influenza viruses generated by reverse genetics
Cell supernatants containing recombinant viruses were used to determine the sensitivity to zanamivir, oseltamivir, peramivir and 4-aminoNeu5Ac2en in the CL-based enzyme inhibition assay. Only those influenza mutants for which a stable virus stock could be obtained in the absence of exogenous NA were able to be tested.
Results are shown in Table 3 . It is clear that the E119V mutation in both the A/Sydney/5/97 and A/Tokyo/67 NAs does not alter the sensitivity to zanamivir. As previously seen it does confer a decrease in sensitivity in both NAs to oseltamivir, although only between 10-and 20-fold, which is less than reported by others for more recent clinical isolates. 18, 21, 32 We show here for the first time that the E119V mutant NA also demonstrates a significant decrease in sensitivity to 4-AminoNeu5Ac2en, of between 50-and 100-fold. This confirms that resistance of the E119V to oseltamivir is due to altered interactions in the region of the 4-amino group. Oseltamivirspecific resistance was also demonstrated with E119V FLAG and E119GrevV mutant NAs. In contrast, the rVic/Sydney NA E119D mutant NA showed a 32-fold increase in zanamivir resistance, but only a small increase in resistance to oseltamivir and peramivir.
As has been observed by others, 34 the H274Y conferred minimal, if any, resistance in the N2 NAs.
Consistent with earlier results the R292K mutation conferred a low level of resistance to zanamivir, peramivir and 4-AminoNeu5Ac2en, but very high resistance to oseltamivir. 6, 7, 10, 18 An rVic/Sydney R152K mutant virus was isolated, but the NA activity of the virus preparation was too low for a drug sensitivity assay. Results generated with a concentrated virus preparation showed a low level of resistance only to zanamivir and an even smaller level of resistance to oseltamivir (data not shown).
Recombinant NA expressed in insect cells Drug sensitivity was determined using the fluorescence-based enzyme inhibition assay on detergent-treated cell extracts. The H274Y mutation in the A/Tokyo/67 N2 NA expressed in insect cells conferred a very low level of resistance to both zanamivir and oseltamivir (Table 4) , consistent with results obtained for our reverse genetics generated rVic/Tokyo H274Y mutant virus grown in MDCK cells (Table 3) . Interestingly the N9 H274Y mutant NA displayed a high level of 
AA, amino acid; neg, no virus rescued. Underlining indicates that the progeny differ from the original mutant.
Influenza N2 neuraminidase mutations 727 resistance to oseltamivir, thus demonstrating N1-like sensitivity. 19, 21, 32 Hence, as mutations conferring specific resistance in either N2 (R292K) or N1 (H274Y) NAs also both confer resistance in the N9 NA, the N9 NA therefore must share some structural characteristics of the N1 NA in the region of the H274, but in contrast, share N2-like characteristics in the R292 region.
Although the R152K mutation in influenza B confers around a 100-fold increase in resistance to zanamivir using the fluorescent assay, 21 this mutation only conferred a low level of resistance to zanamivir and even less to oseltamivir in the A/Tokyo/67 N2 NA (Table 4) , which is consistent with the results obtained in our reverse genetics generated influenza viruses. The N9 R152K NA demonstrated a slightly higher level of resistance to zanamivir (9.6·) than to oseltamivir compared with the N2 NA, although still much lower than seen in the B NA. Both the R152K NAs were surprisingly more sensitive to 4-AminoNeu5Ac2en. In addition, although the data show that N9 NA has similarities with the N2 NAs in the region of R152 there must still be subtle differences, since the R152K mutation conferred resistance to peramivir in the G70C N9 NA, but had no effect on sensitivity of the A/Tokyo/67 N2 NA to peramivir.
Relative activity of mutant NAs
Recombinant A/Sydney/5/97 NAs expressed in 293T cells To understand why some of the mutant NAs did not appear to result Values are the means of at least two experiments. Values given in boldface are those demonstrating the greatest decrease in drug sensitivity.
a Relative activity was calculated as the ratio of the amount of NA protein, based on the A 405 in an ELISA capture assay using a conformational specific monoclonal anti-NA antibody, to the amount of enzyme activity in the corresponding dilutions in a MUNANA-based assay.
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in the production of viable virus the relative activity of the mutant NAs was measured as some of the NA mutations are known to affect enzyme function or stability. 29 To determine the relative NA activity the levels of protein expressed and the NA activity were measured in 293T cells transfected with the four helper plasmids and each NA plasmid using the pPRG expression system. We have previously shown that the most accurate measurement of the relative activity of mutant NAs depends on having a conformational specific monoclonal antibody to determine the levels of correctly folded NA protein. 29 However, in the absence of monoclonal antibodies specific for the A/Sydney N2 NA, levels of wild-type and mutant NA proteins expressed on the cell surface of 293T cells were determined by FACS analysis using a variety of antisera. NA activity was measured by the CL assay using whole cells from the same batch of transfected cells.
For the efficient detection of the expressed NA protein a portion of the NA stalk was replaced with the FLAG epitope (DYKDDDDK) as previously shown by others. 27 In order to test for the functionality of the modified NA-FLAG we rescued wildtype and mutant NA-FLAG viruses, which showed the same phenotype as their non-FLAG equivalents (data not shown, Table 3 ), indicating that the FLAG epitope did not alter viability of rescued virus in MDCK cells. Three different staining regimens were used for FACS analysis, an anti-N2 polyclonal serum, or an anti-FLAG monoclonal antibody or dual staining with both antisera. The same results were obtained using the three different methods (data not shown). Table 5 shows the results of the dual staining experiments.
The results showed that similar levels of NA protein were detected on the surface of the 293T cells expressing the wild-type or mutant NAs, with the exception of the E119G and E119A mutant NAs, where 2-to 4-fold lower levels of NA protein were detected (see Table 5 ).
However, significant differences in NA activity in the cell suspension and the relative activity were observed for several mutants. The relative activities for the three mutant NAs E119G, A and R152K were all extremely low, <6%, consistent with the inability to recover viable virus maintaining these mutations. In contrast, NAs with the mutations E119V and R292K, which are seen in current H3N2 clinical isolates after oseltamivir treatment, 18 all had higher NA activities (28-45%). The NA activities of these mutants were still less than that of the wild-type NA but were clearly sufficient for virus replication in a cell culture system. Although the H274Y mutation did not significantly affect drug susceptibility it did appear to have some effect on the relative enzyme activity of the A/Sydney/5/97 NA, as it had only one-third of the wild-type enzyme activity. Although the E119D NA only had 15% of the activity of the wild-type NA, infectious virus could be rescued (Table 3) .
Levels of expression of the R152K mutant NA were greater than or equal to the levels of wild-type NA with all three staining regimens. However, the relative NA activity was <1%. Rescued virus reverted back to wild-type in the absence of bacterial NA in the case of the rVic/Sydney and rVic/Tokyo NA K152 mutants. However, for the rVic/Sydney R152K mutant in one of two independent experiments virus was isolated which maintained the mutation for one passage. No compensating mutation in the HA gene was present and it is not clear how this virus would replicate with such low NA activity. The activity and/or stability of the mutant R152K NA might be altered when expressed in the context of the virus, compared with the expression from plasmids.
Recombinant NA expressed in insect cells The R152K and H274Y mutations had a large effect on the activity of the N9 mutant NAs (Table 4) , similar to the effects seen in the A/Sydney/5/97 mutant N2 NAs expressed in the 293T cells (Table 5 ). Relative activity of the A/Tokyo/67 H274Y NA expressed in insect cells was only slightly less than that of the wild-type NA and was slightly higher than seen for the A/Sydney/5/97 H274Y NA expressed in the 293T cells. A much larger difference was seen between the specific activities of the A/Tokyo/67 R152K mutant NA expressed in insect cells (35% Table 4 ) and the A/Sydney/5/97 R152K NA expressed in the 293T cells (0.1% Table 5 ). This may be due to differences in the amino acid sequence (89% homology). Alternatively it may be due to instability of the mutant enzymes. We have previously shown that to measure relative specific activity of an unstable enzyme it is critical that only correctly folded NA be measured for NA protein concentration. 29 The various antisera used to detect the levels of NA expressed in the 293T cells would detect all NA, thus giving a lower value for relative NA activity if significant levels of inactive or misfolded NA were present. As we used a conformational specific monoclonal antibody for capture of the A/Tokyo/67 NA produced in insect cells this would only detect correctly folded NA and would therefore give a more accurate value for specific activity if the NAs were unstable.
Stability of the baculovirus-expressed N2 R152K
A/Tokyo/67 NA We wished to investigate whether the R152K NA was unstable, but we were unable to obtain preparations of the A/Sydney/5/97 NA with sufficient enzyme activity to follow further inactivation. Since the E119VG and H274Y mutations conferred similar properties to both the A/Sydney/5/97 and A/Tokyo/67 NAs ( Table 3 ) we reasoned that the R152K mutant NAs would also share similar properties. Hence we used insect cells expressing the A/Tokyo/67 NA to investigate the effect of this mutation on Influenza N2 neuraminidase mutations 729 enzyme stability. Insect cells expressing the A/Tokyo/67 R152K NA were lysed, and aliquots were incubated at 37, 45, 50, 55 and 60 C for 1 h. The residual activity was compared with the activity of a sample held at 4 C. As seen in Figure 2 , the A/Tokyo/67 R152K NA was more unstable even at 37 C compared with the wild-type NA. Thus instability of the R152K mutant enzymes could account for the large differences in the apparent specific activities of the A/Tokyo/67 and A/Sydney/5/97 NAs, since the quantification of the A/Sydney/5/97 NA relies on polyclonal antisera that will detect all NAs that are correctly transported but will include inactive enzyme, whereas the monoclonal antibody used to quantify the A/Tokyo/67 NA only detects active NA.
Kinetics of replication
Growth of four stable rVic/Sydney mutant viruses was compared in MDCK cells infected with an moi of 0.001. Kinetics of replication of the E119V mutant was identical to those of the wild-type virus (Figure 3) . Mutant R292K had a slower rate of growth, but did eventually grow to the same titre as the wild-type virus. This suggests that the suboptimal NA had some effect, but not sufficient to decrease virus yields in a culture system. As seen in Figure 3 , the E119D mutation had the most dramatic effect on reducing virus yield. This NA only had 15% of the activity of the wild-type NA.
Discussion
Previously the minimalist hypothesis of drug design has been proposed, which suggests that the closer the inhibitor is to the natural ligand, the less likely the target can mutate to avoid binding drug, while still maintaining viable function. 7 This predicted that resistance would be more likely to arise to oseltamivir than to zanamivir, due to the modifications of oseltamivir at both the 4 and 6 positions compared with the natural ligand, DANA. This prediction has been borne out in clinical practice with resistance being seen in oseltamivir-treated patients, 18, 19 but not in clinical studies in immunocompetent patients treated with zanamivir. 35 However, it is known that resistance to zanamivir can be generated in viruses passaged in vitro, 36 but no viruses bearing these mutations have yet been isolated from patients treated with zanamivir. Two recombinant systems were used to investigate why resistant viruses may not be readily isolated from patients treated with zanamivir and to further explore subtype-specific resistance mutations. Although viruses with mutations at amino acid 119 have been generated in vitro, some of the strains used as the model viruses have been from an avian background, NWS/G70C (H1N9) or A/Turkey/ Minnesota (H4N2). Here we used reverse genetics to generate viruses with NAs from a more recent human clinical isolate, A/Sydney/5/97 (H3N2) as well as the human derived NA from the A/Tokyo/67 (H3N2) virus used in the design of zanamivir. Using reverse genetics, recombinant influenza viruses generated with E119G and E119A mutations associated with zanamivir resistance in vitro 9,11 did not stably maintain the mutant NA. The mutant NA either reverted to the wild-type NA or mutated to one that was less deleterious to the viability of the viruses. Unexpectedly both viruses most commonly acquired an E119V mutation. This was true not only for viruses with the recent A/Sydney/5/97 N2 NA, but also with the N2 NA from the A/Tokyo/67 virus. The E119V mutation is seen in N2 viruses isolated from patients treated with oseltamivir, so viruses with this mutation are known to be viable. 18 There was a correlation between the relative NA activity of the mutant NAs and the viability of the progeny virions. Those with <5% of the wild-type NA activity did not generate stable progeny.
This suggests that even if a virus with an E119G or E119A mutation was generated after zanamivir treatment it may not survive, possibly explaining the lack of isolation of E119 resistant viruses from zanamivir-treated patients. Hence although the E119G and E119A mutations have been demonstrated in vitro in avian type A NAs and influenza B virus NA, 12, 14, 20 they would seem to be unstable in both current and past human N2 NAs. Hence the lack of resistance seen to date in zanamivir-treated immunocompetent patients could be accounted for by zanamivir being closer to the natural substrate and hence mutations which confer resistance to zanamivir also compromise the binding of sialic acid, resulting in poor enzyme activity. Due to the poor viability of these zanamivir-resistant mutant viruses, the mutations are not stably maintained and wild-type or other fitter viruses are rapidly selected.
Although there is a high degree of conservation of residues in the active site, there are clearly subtle differences between N1, N2, N9 and B NAs. In addition to there being N1 and N2 subtypespecific NA mutations, such as H274Y (N1), E119V (N2) and R292K (N2), some mutations that confer resistance in the NAs of different subtypes vary in the magnitude of resistance they confer. The R152K, E119V and E119D mutations only conferred a low to medium level of resistance in the N2 NAs used here, whereas in the influenza B NAs these three mutations all conferred a high level of resistance. 20 Even within the N2 subtype of NA we see differences in the magnitude of resistance between avian or human NAs, for example the E119D conferred a high level of resistance in the Turkey N2 NA, 9 but only 30-fold resistance in the human A/Sydney/5/97 NA here. One known difference between avian and human NAs is the presence of a second sialic binding site in avian NAs. 37 There are obviously further differences outside those conserved residues in the active site, to account for the differences in the sensitivities of the mutant NAs. Hence, not only are there differences between N1 and N2 NAs, which can impact on binding of inhibitor, but there are obviously additional subtle differences within the NA subtypes. Determination of the structure of an N1 NA, which has not yet been done, would greatly enhance our knowledge of the differences that could account for the subtype-specific N1/N2 resistance seen to the NA inhibitors. Comparison of avian and human N2 structures would also help elucidate the roles of residues outside the active site which affect NA stability and inhibitor resistance. We have also demonstrated here that the G70C N9 NA has properties of both N1 and N2 NAs, as mutations which have been shown to be N2-specific (R292K) 7, 10 or N1-specific (H274Y) 16, 19 both confer a high level of resistance in the recombinant N9 NA studied here. In addition, Molla et al.
38 also previously reported that E119V found in N2 NAs conferred resistance in the N9 NA. Since as yet we have no structure of an N1 NA, but the structure of the N9 NA is well studied, 7, 37, [39] [40] [41] the N9 NA may provide a useful model for investigating the structural basis of subtype-specific drug resistance.
